Trial finds no significant COVID effect of pre-exposure hydroxychloroquineA randomized, controlled clinical trial involving high-risk healthcare workers found that pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce COVID-19 compared with placebo, researchers reported late last week in Clinical Infectious Diseases.The randomized, double-blind trial, led by researchers with the University of Minnesota, enrolled 1,483 healthcare workers in the United States and Manitoba from Apr 6 to May 26.
Participants were assigned in a 2:2:1:1 ratio to receive 400 milligrams of hydroxychloroquine once weekly or twice weekly for 12 weeks or placebo prescribed in a matched fashion.